Mifepristone and misoprostol sequential regimen side effects, complications and safety

Contraception

Volumn 74, Issue 1, 2006, Pages 48-55

  Sitruk Ware, Regine ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antiglucocorticoid; Antiprogesterone; Mifepristone; Misoprostol; Safety; Termination of pregnancy

Indexed keywords

CARBAMAZEPINE; CORTICOTROPIN; DEXAMETHASONE; ERYTHROMYCIN; GEMEPROST; ITRACONAZOLE; KETOCONAZOLE; MIFEPRISTONE; MISOPROSTOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RINGER SOLUTION; SULPROSTONE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE HEART INFARCTION; BACTERIAL INFECTION; BLOOD TRANSFUSION; CONGENITAL MALFORMATION; CORONARY ARTERY SPASM; CORTICOTROPIN RELEASE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; EMBRYOTOXICITY; ENDOMETRITIS; ESTRUS; FACE EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HORMONAL CONTRACEPTION; HORMONE INHIBITION; HUMAN; HYPERMENORRHEA; HYPOTENSION; INFECTION COMPLICATION; KIDNEY FAILURE; MALAISE; MASTALGIA; MENSTRUATION DISORDER; NAUSEA; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PREGNANCY TERMINATION; PROGESTERONE SYNTHESIS; REVIEW; SALPINGITIS; SEPTIC SHOCK; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; TREATMENT INDICATION; URTICARIA; UTERINE CERVIX DILATATION; UTERUS BLEEDING; UTERUS CONTRACTION; VAGINA DISCHARGE; VITAL SIGN;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PELVIC INFECTION; PREGNANCY; UTERINE HEMORRHAGE;

EID: 33745016281     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.016     Document Type: Review

References (42)

1. Deraedt R., Vannier B., and Fournex R. Toxicological study on RU 486. In: Baulieu E.E., and Segal S.J. (Eds). The antiprogestin steroid RU 486 and human fertility control (1985), Plenum Press, New York 123-126
2. Jost A. New data on the hormonal requirements of the pregnant rabbit: partial pregnancies and fetal abnormalities after treatment with a hormonal antagonist at subabortifacient doses. C R Acad Sci 303 series III, no. 7 (1986) 281-284
3. Moguilewsky M., and Philibert D. Biochemical profile of mifepristone. In: Baulieu E.E., and Segal S.J. (Eds). The antiprogestin steroid RU 486 and human fertility control (1985), Plenum Press, New York 87-97
4. Vander Schoot P., and Baumgarten R. Effects of treatment of male and female rats in infancy with mifepristone on reproductive function in adulthood. J Reprod Fertil 90 (1990) 255-266
5. Bertagna X., Bertagna C., Luton J.P., Husson J.M., and Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59 (1984) 25-28
6. Gaillard R.C., Poffet D., Riondel A.M., and Saurat J.H. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 61 (1985) 1009-1011
7. Bertagna X., Escourolle H., Pinquier J.L., et al. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 78 (1994) 375-380
8. Spitz I.M., Grunberg S.M., Chabbert-Buffet N., Lindenberg T., Gelber H., and Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 84 (2005) 1719-1726
9. Jang G.R., Wrighton S.A., and Benet L.Z. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 52 (1996) 753-761
10. Mifeprex labeling at http://www.fda.gov/cder/foi/label/2000/20687lbl.htm.
11. Sitruk-Ware R. Approval of mifepristone (RU 486) in Europe. Zentralbl Gynakol 122 (2000) 241-247
12. Swahn M.L., and Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 95 (1988) 126-134
13. Urquhart D.R., and Templeton A.A. Mifepristone (RU 486) for cervical ripening prior to surgically induced abortion in the late first trimester. Contraception 42 (1990) 191-199
14. Peyron R., Aubény E., Targosz V., Silvestre L., Renault M., Elkik F., et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 328 (1993) 1509-1513
15. Aubény E., Peyron R., and Baulieu E.E. Termination of early pregnancy (up to and after 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. Int J Fertil 40 Suppl 2 (1995) 85-91
16. Urquhart D.R., Templeton A.A., Shinewi F., et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicenter study - final results. Contraception 55 (1997) 1-5
17. Spitz I.M., Bardin C.W., Benton L., and Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 338 (1998) 1241-1247
18. Ulmann A., Silvestre L., Chemama L., et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand 71 (1992) 278-283
19. Henderson J.T., Hwang A.C., Harper C.C., and Stewart F.H. Safety of mifepristone abortions in clinical use. Contraception 72 (2005) 175-178
20. Henderson J.T., Hwang A.C., Harper C.C., and Stewart F.H. Correction: safety of mifepristone abortions in clinical use. Contraception 72 Suppl (2005) 175-178
21. Anonymous. A death associated with mifepristone/sulprostone. Lancet 337 (1991) 969-970
22. FDA public health advisory. Sepsis and medical abortion. http://www.fda.gov/cder/drug/advisory/mifeprex.htm.
23. Sinave C., Le Templier G., Blouin D., Léveillé F., and Deland É. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 35 (2002) 1441-1443
24. Fischer M., Bhatnagar J., Guarner J., et al. Fatal toxic shock syndrome associated to Clostridium Sordellii, after medical abortion. N Engl J Med 353 (2005) 2352-2360
25. Knudsen U.B. First trimester abortion with mifepristone and vaginal misoprostol. Contraception 63 (2001) 247-250
26. Schaff E.A., Fielding S.L., Eisinger S., and Stadalius L. Mifepristone and misoprostol for early abortion when no gestational sac is present. Contraception 63 (2001) 251-254
27. Shannon C., Brothers L.P., Philip N.M., and Winikoff B. Infection after medical abortion: a review of the literature. Contraception 70 (2004) 183-190
28. Henshaw R.C., Naji S.A., Russell I.T., and Templeton A.A. A comparison of medical abortion (using mifepristone and gemeprost) with surgical vacuum aspiration: efficacy and early medical sequelae. Hum Reprod 9 (1994) 2167-2172
29. Lichtenberg E.S., Grimes D.A., and Paul M. Abortion complications: prevention and management. In: Paul M., Lichtenberg E.S., Borgatta L., Grimes D.A., and Stubblefield P.G. (Eds). A clinician's guide to medical and surgical abortion (1999), Churchill Livingstone, New York 1693-1707
30. Cameron S.T., Glasier A.F., Logan J., Benton L., and Baird D.T. Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. Br J Obstet Gynaecol 103 (1996) 1222-1229
31. Van der Schoot P. Treatment with mifepristone (RU 486) and oestradiol facilitates the development of genital septic disease after copulation in female rats. Human Reprod 7 (1992) 601-605
32. Greene M. Fatal infections associated with mifepristone-induced abortions. [Editorial]. N Engl J Med 353 (2005) 2317-2318
33. Bitti A., Mastrantonio P., Spigaglia P., Urru G., Spano A.I., Moretti G., et al. A fatal postpartum Clostridium sordellii associated toxic shock syndrome. J Clin Pathol 50 (1997) 259-260
34. Fiala C. PhD thesis. Improving medical termination of pregnancy. Karolinska Institute, Stockholm, Sweden, October 2005.
35. Miech R.P. Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Ann Pharmacother 39 (2005) 1483-1488
36. Laue L., Lotze M.T., Chrousos G.P., Barnes K., Loriaux D.L., and Fleisher T.A. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab 71 (1990) 1474-1480
37. Sitruk-Ware R., Davey A., and Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet 352 (1998) 323
38. Pons J.-C., Imbert M.-C., Elefant E., et al. Development after exposure to mifepristone in early pregnancy. Lancet 338 (1991) 763
39. Gary M.M., and Harrison D.J. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother 40 (2006) 191-197
40. Sitruk-Ware R. Medical recommendations for the safe use of mifepristone. In: Coutinho E.M., and Spinola P. (Eds). Reproductive medicine. A millenium review (1999), Parthenon Publishing group, London 288-299
41. Sitruk-Ware R., and Spitz I. Pharmacological properties of mifepristone toxicology and safety in animal and human studies. Contraception 68 (2003) 409-420
42. Ho P.C., Yu Ng E.H., and Tang O.S. Mifepristone: contraceptive and non-contraceptive uses. Curr Opin Obstet Gynecol 14 (2002) 325-330